Globally cancer is the second leading cause of death while the economic burden of cancer is worsening. Exploiting 3D microfluidic approaches, subjecting the patient to specific tumour biopsies in their microfluidic device. The startup, mimicking the relevant pathophysiological conditions, will be able to predict the right combination of drugs that can work with high efficacies.
The device will play an immense role in personalized therapies; especially in cancer patients.
Microfluidic Device platforms for personalized cancer treatments.
Disclaimer: The information shared in the document is provided by the startup. iTIC shall not be held responsible for the information shared by the startup.
